📊 PALI Key Takeaways
Is Palisade Bio, Inc.. (PALI) a Good Investment?
Palisade Bio is a pre-revenue stage biotech company with exceptional liquidity ($133.4M cash) but zero commercial traction, active cash burn of $10.8M annually, and value destruction evident in negative ROE/ROA. While the balance sheet provides 12+ years of runway, the fundamental absence of revenue, ongoing losses, and lack of visible profitability pathway make this a high-risk speculation without clinical or commercial validation.
Why Buy Palisade Bio, Inc.. Stock? PALI Key Strengths
- Exceptional liquidity: $133.4M cash with 28.95x current ratio
- Minimal debt burden: Only $87K long-term debt with 0.0x debt-to-equity
- Strong equity cushion: $129.4M stockholders' equity provides substantial R&D funding runway (12+ years at current burn rate)
PALI Stock Risks: Palisade Bio, Inc.. Investment Risks
- Zero revenue: No commercial product validation or market traction
- Active cash burn: -$10.8M operating cash flow annually destroying shareholder value
- Pre-commercialization risk: All profitability metrics N/A; no visible path to profitability or timeline disclosed
- Typical biotech execution risks: Clinical trial failures, regulatory rejection, delayed timelines not quantified
Key Metrics to Watch
- Operating cash burn trajectory and cash runway depletion timeline
- Clinical trial progress milestones and regulatory pathway advancement
- Revenue recognition date and initial commercial adoption metrics
- Operating expense efficiency and R&D productivity
Palisade Bio, Inc.. (PALI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 28.95x current ratio provides a solid financial cushion.
PALI Profit Margin, ROE & Profitability Analysis
PALI vs Healthcare Sector: How Palisade Bio, Inc.. Compares
How Palisade Bio, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Palisade Bio, Inc.. Stock Overvalued? PALI Valuation Analysis 2026
Based on fundamental analysis, Palisade Bio, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Palisade Bio, Inc.. Balance Sheet: PALI Debt, Cash & Liquidity
PALI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Palisade Bio, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-10.19 indicates the company is currently unprofitable.
PALI Revenue Growth, EPS Growth & YoY Performance
PALI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | N/A | -$3.5M | $-2.32 |
| Q2 2024 | N/A | -$3.4M | $-3.32 |
| Q1 2024 | N/A | -$2.3M | $-4.59 |
| Q3 2023 | N/A | -$3.6M | $-0.49 |
| Q2 2023 | N/A | -$2.3M | $-0.53 |
| Q1 2023 | N/A | -$2.3M | $-0.54 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Palisade Bio, Inc.. Dividends, Buybacks & Capital Allocation
PALI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Palisade Bio, Inc.. (CIK: 0001357459)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PALI
What is the AI rating for PALI?
Palisade Bio, Inc.. (PALI) has an AI rating of SELL with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PALI's key strengths?
Claude: Exceptional liquidity: $133.4M cash with 28.95x current ratio. Minimal debt burden: Only $87K long-term debt with 0.0x debt-to-equity.
What are the risks of investing in PALI?
Claude: Zero revenue: No commercial product validation or market traction. Active cash burn: -$10.8M operating cash flow annually destroying shareholder value.
What is PALI's revenue and growth?
Palisade Bio, Inc.. reported revenue of $0.0.
Does PALI pay dividends?
Palisade Bio, Inc.. does not currently pay dividends.
Where can I find PALI SEC filings?
Official SEC filings for Palisade Bio, Inc.. (CIK: 0001357459) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PALI's EPS?
Palisade Bio, Inc.. has a diluted EPS of $-0.30.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PALI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Palisade Bio, Inc.. has a SELL rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PALI stock overvalued or undervalued?
Valuation metrics for PALI: ROE of -13.0% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PALI stock in 2026?
Our dual AI analysis gives Palisade Bio, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PALI's free cash flow?
Palisade Bio, Inc..'s operating cash flow is $-10.8M, with capital expenditures of $0.0.
How does PALI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -13.0% (avg: 15%), current ratio 28.95 (avg: 2).